IMPACT THERAP-B (07630.HK): Board Approves Up to HK$100m H-Share Buyback

NewTimeSpace News: On 4 November 2026, IMPACT Therapeutics, Inc. (stock code: 07630) announced that its Board has resolved to repurchase its H shares on the open market of the Stock Exchange from time to time, under the general mandate approved by shareholders at the annual general meeting held on 25 June 2026, for a total amount not exceeding HK$100 million, including brokerage commission, stamp duty and other transaction costs.

The buyback mandate runs from the date the relevant resolution was passed until the earliest of the conclusion of the next annual general meeting, the expiry of the period within which the next annual general meeting must be held under the articles of association or applicable PRC laws, and the date on which shareholders revoke or vary the mandate by special resolution. The repurchases will be funded from the Company's own financial resources, excluding proceeds from its global offering. As at the date of the announcement, no H shares had been repurchased under the mandate.

The Board considers the buyback necessary and reasonable in light of the trading performance of the H shares, the Company's business and financial position, funding needs and the overall interests of shareholders, and believes it demonstrates confidence in the Company's business outlook and prospects and will ultimately create value for shareholders. The Company's current financial resources are sufficient to implement the buyback while maintaining a sound financial position. Repurchased shares will subsequently be cancelled and/or held as treasury shares as the Board considers appropriate, and the buyback will not reduce the number of H shares held by the public below the minimum percentage required by the Listing Rules.